Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Is Soaring Today

By Keith Speights - Feb 4, 2021 at 12:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are reacting positively to an analyst's upgrade.

What happened

Shares of Ocugen (OCGN -0.45%) were soaring 17.4% higher as of 11:53 a.m. EST on Thursday. The big gain came after H.C. Wainwright analyst Swayampakula Ramakanth upgraded the stock to a buy rating from neutral. 

So what

Should investors buy a biotech stock like Ocugen just because an analyst upgrades it? Nope. However, it's wise to examine why an analyst thinks highly (or negatively) of a stock.

Hand holding a vaccine vial and a syringe with scientists, a microscope, and a test tube rack in the background

Image source: Getty Images.

In this case, Ramakanth is very bullish about Ocugen. He set a one-year price target of $4.50 -- a 60% premium to Ocugen's closing price on Wednesday. 

What's fueling this optimism? Ramakanth really likes the deal that Ocugen made with Bharat Biotech that was announced earlier this week. Under this agreement, Ocugen will co-develop, supply, and commercialize Bharat's Covaxin experimental COVID-19 vaccine for the U.S. market.

If Covaxin obtains Emergency Use Authorization (EUA) or approval in the U.S., Ocugen will make 45% of the profits from the vaccine. The vaccine has already received EUA in India. However, no clinical studies have been conducted for Covaxin in the U.S. at this point.

Now what

The enthusiasm about Ocugen could evaporate if Covaxin doesn't make it to the U.S. market. Ocugen has already begun talking with the U.S. Food and Drug Administration (FDA) about a potential path to EUA and ultimately approval. The results from these discussions will be critically important as to whether or not the biotech stock can keep its momentum going.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.23 (-0.45%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.